MRD responses and outcomes in patients with NPM1 mutated AML achieving CR/CRi with venetoclax-based therapies. (A) Best MRD response by the end of cycles 1 to 6, and overall. (B) Overall survival by achievement of MRD negativity in first 4 cycles. (C) EFS by achievement of MRD negativity in first 4 cycles. (D) Cumulative incidence of relapse by achievement of MRD negativity in first 4 cycles. (E) Rates of MRD negativity in the first 4 cycles in patient subgroups. C1, cycle 1; C2, cycle 2; C3, cycle 3; C4, cycle 4; C5, cycle 5; C6, cycle 6; ITD, internal tandem duplication; Mut, mutated; TKD, tyrosine kinase domain; WT, wild type.